^
Association details:
| Biomarker: | CDC25C overexpression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma
Published date:
04/29/2022
Excerpt:
...data regarding 7 LUAD samples were collected to further analyze the effect of CDC25C on the survival of LUAD patients treated with nivolumab. Notably, the analysis demonstrated that higher CDC25C expression was associated with shorter PFS (high vs. low: 1.0 month vs. 8.55 months, P = 0.0143)...
DOI:
10.3389/fonc.2022.867788